Literature DB >> 3983886

Adverse reactions to piperacillin in adults with cystic fibrosis.

R J Stead, H G Kennedy, M E Hodson, J C Batten.   

Abstract

Nine adult patients with cystic fibrosis, nearly a quarter of the 38 patients with this disease who were treated with piperacillin (59 courses in all) during 1981-3 at the Brompton Hospital, developed a swinging pyrexia after a mean of 13.5 days' treatment with this antibiotic. The fever resolved shortly after the piperacillin treatment was stopped, as did the widespread rashes in the two patients who developed them. Three of four patients who had probable reactions to azlocillin may have been sensitised by piperacillin. As piperacillin does not appear to be any more effective than other antipseudomonal penicillins in cystic fibrosis, it is no longer used at the hospital for treating bronchopulmonary exacerbations in such patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3983886      PMCID: PMC460021          DOI: 10.1136/thx.40.3.184

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  5 in total

1.  Adverse reactions to piperacillin in cystic fibrosis.

Authors:  R J Stead; H G Kennedy; M E Hodson; J C Batten
Journal:  Lancet       Date:  1984-04-14       Impact factor: 79.321

2.  Adverse reactions to piperacillin in patients with cystic fibrosis.

Authors:  B Strandvik
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

3.  Piperacillin therapy for serious bacterial infections.

Authors:  D J Winston; W Murphy; L S Young; W L Hewitt
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

4.  Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

5.  Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin.

Authors:  N E Møller; K R Eriksen; C Feddersen; E W Flensborg; N Høiby; S Norn; K Rosendal; P O Schiøtz; P S Skov
Journal:  Eur J Respir Dis       Date:  1982-03
  5 in total
  6 in total

Review 1.  Drug allergy in cystic fibrosis.

Authors:  R B Moss
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

2.  Immune-mediated severe hemolytic crisis with a hemoglobin level of 1.6 g/dl caused by anti-piperacillin antibodies in a patient with cystic fibrosis.

Authors:  S Kunzmann; W Thomas; B Mayer; S Kuhn; H Hebestreit
Journal:  Infection       Date:  2010-03-05       Impact factor: 3.553

Review 3.  The pulmonary physician in critical care. Illustrative case 1: cystic fibrosis.

Authors:  S R Thomas
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

Review 4.  Antibiotic hypersensitivity in patients with CF.

Authors:  Sujatha Ramesh
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

5.  [Acute interstitial nephritis following piperacillin].

Authors:  O Dörner; C Piper; H P Dienes; P A Berg; H von Egidy
Journal:  Klin Wochenschr       Date:  1989-07-03

6.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.